Table 5.
Outcome
| SWIFT PRIME |
MR CLEAN |
ESCAPE |
EXTEND IA |
REVASCAT |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| intervention | control | intervention | control | intervention | control | intervention | control | intervention | control | |
| Revascularization TICI 2b-3 | 88% | 58.7% | 72.4% | 86% | 65.7% | |||||
| Proportion with mRS at 90 days ≤2 | 60% | 35% | 32.6% | 19.1% | 53.0% | 29.3% | 71% | 40% | 43.7% | 28.2% |
| Adjusted OR (95% CI) | 2.03 (1.36 – 3.03) | 2.16 (1.39 – 3.38) | 3.1 (2.0 – 4.7)a | 4.2 (1.4 – 12) | 2.1 (1.1 – 4.0) | |||||
| Mortality at 30 days | 9% | 12% | 18.4% | 18.9% | 10.4% | 19.0% | 9% | 20% | 18.4% | 15.5% |
| Sich | 0% | 3% | 7.7% | 6.4% | 3.6% | 2.7% | 0% | 6% | 1.9% | 1.9% |
a
Common adjusted OR for primary mRS.